Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

NextEdge Admin

08 Nov 2024

2 min 26 sec

immune checkpoint inhibitor,immunotherapy

Tempus AI, Inc. , a leading technology company in precision medicine, has launched its Immune Profile Score (IPS) algorithmic test, now available for clinicians treating adult patients with stage IV and metastatic solid tumors who are candidates for immune checkpoint inhibitor (ICI) therapy. The IPS test is a multimodal biomarker that provides a prognostic score, potentially guiding patient care by identifying those who might benefit from ICI therapy.

Tempus is presenting the validation study results for IPS at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The study of 1,600 patients with various solid tumor types demonstrated that IPS-High patients showed an improved overall survival rate on ICI therapy compared to IPS-Low patients (HR 0.45). Unlike other markers, IPS offers independent prognostic utility beyond tumor mutational burden (TMB), PD-L1 immunohistochemistry (IHC), and microsatellite instability (MSI) status.

The IPS test, a laboratory-developed test, generates a score from 0 to 100 and classifies patients as IPS-Low or IPS-High by analyzing immunotherapy-related biomarkers from DNA and RNA data. This approach aims to enhance treatment precision in clinical practice and support life sciences research by expanding the indications for ICI therapies.

“This is Tempus' first multimodal algorithm for immunotherapy,” stated Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus. “We’re providing clinicians with data-driven insights to inform critical treatment decisions.” Clinicians can now order the IPS test as an add-on to Tempus’ xT (DNA) and xR (RNA) assays, facilitating a more tailored approach to immunotherapy.